- Home
- SENEA vs KOD Comparison
SENEA vs KOD Comparison
Compare SENEA & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEA | KOD |
|---|---|---|
| Founded | 1949 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.1M | 795.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SENEA | KOD |
|---|---|---|
| Price | $111.90 | $22.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.67 |
| AVG Volume (30 Days) | 82.1K | ★ 720.6K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | N/A |
| Revenue | ★ $1,606,175,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.87 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $70.58 | $1.92 |
| 52 Week High | $129.03 | $26.21 |
Technical Indicators
Market Signals| Indicator | SENEA | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 54.93 |
| Support Level | $109.05 | $21.24 |
| Resistance Level | $113.83 | $26.21 |
| Average True Range (ATR) | 4.27 | 1.67 |
| MACD | -1.18 | -0.16 |
| Stochastic Oscillator | 14.01 | 40.65 |
Price Performance
Historical ComparisonAbout SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.